1. Study shows MicroPulse TLT effectively reduces IOP in glaucoma patients. 2. Retreatment led to IOP reductions of 25% to 35% in 76 eyes studied. 3. Results affirm MicroPulse TLT's safety and repeatability in glaucoma management. 4. Patients’ retreatment intervals varied, indicating flexible treatment options. 5. CEO emphasizes commitment to clinical evidence supporting MicroPulse TLT.
FAQ
Why Bullish?
The positive results from the study on MicroPulse TLT could lead to increased sales. Historical trends show that similar study outcomes boost stock prices in the medical device sector.
How important is it?
The study’s findings directly relate to IRIDEX's core product, likely boosting market interest. Positive clinical evidence can attract new partnerships and expansion in both domestic and international markets.
Why Long Term?
As awareness and adoption of MicroPulse TLT increase over time, it can significantly enhance revenue. Long-term market penetration will improve IRIX's position in glaucoma treatments.
Iridex Corporation Publishes Promising Study on Glaucoma Treatment
MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a prominent player in the development of innovative laser-based medical systems, has announced the publication of an independent, retrospective study in the journal Ophthalmology and Therapy. This groundbreaking study highlights the safety and effectiveness of retreatment using MicroPulse® technology (MicroPulse TLT) for reducing intraocular pressure (IOP) in glaucoma patients.
Study Overview and Findings
Conducted at the University Eye Clinic Maastricht, the study assessed the effectiveness, repeatability, and safety of MicroPulse TLT retreatment in a real-world clinical setting. It involved 76 eyes from patients experiencing moderate to advanced glaucoma, who underwent this retreatment following varied responses to their initial procedures.
Key findings of the study include:
- Reduction in IOP ranged from approximately 25% to 35% across all patient groups three months post-retreatment.
- All patients benefited, regardless of their prior responses to the initial treatment.
- Retreatment timing varied, with an average first retreatment occurring as early as four months to over 28 months post-initial procedure.
Expert Commentary on MicroPulse TLT
Dr. Ronald de Crom, the study's lead author, remarked, “These findings support retreatment with MicroPulse TLT as a valuable option in glaucoma care, particularly for patients who experienced an initial IOP-lowering benefit that diminished over time.” He further noted that the results help clinicians identify which patients are most likely to benefit from retreatment based on their initial response.
Patrick Mercer, President and CEO of Iridex, expressed excitement over the new clinical data: “This study reinforces what we hear from physicians globally, that MicroPulse TLT offers a valuable non-incisional option that can be tailored and repeated over time while maintaining a favorable safety profile.”
Implications for Glaucoma Management
The variability in retreatment timing among participants showcases the individualized nature of glaucoma management, further suggesting that MicroPulse TLT is flexible in maintaining IOP control over time. This adaptability is particularly beneficial for ophthalmologists looking to provide personalized treatment plans for their patients.
About Iridex Corporation
Iridex Corporation is recognized globally for its development, manufacturing, and marketing of advanced laser-based medical systems. They specialize in providing capital equipment and consumable probes specifically designed for ophthalmology applications. Their proprietary MicroPulse® technology enables effective laser treatments while minimizing tissue damage, making it a safe option for addressing serious eye conditions such as glaucoma and diabetic macular edema (DME).
Iridex's products are distributed in over 100 countries, utilizing both a direct sales force in the United States and a network of independent distributors internationally. For more information on Iridex and its innovative technologies, visit www.iridex.com.